The Clinical Research Unit at The Neuro — one of the largest neurological trial centres in Canada — has been at the forefront of cutting-edge therapies for 40 years. Today, the Unit’s efforts to advance treatments are focussed on novel therapeutics which are poised to revolutionize neurological care.

This day-long event will bring together international leaders developing the latest generation of treatments. The symposium is designed for scientists, health professionals and stakeholders from academia and industry involved in the development of novel therapeutics for rare diseases and offers a unique opportunity to connect with international researchers.

The symposium is a satellite of the ASHG2026 annual meeting, and takes place the day before the start of their proceedings.

A leader in his field, Phillip Zamore has been the Chair of the RNA Therapeutics Institute at UMass Chan Medical School for the past decade where his lab sought to understand the biology and mechanism of paradigmatic examples of Argonaute proteins and pathways, and, ultimately, to use these insights to design and improve small RNA-guided therapies for human diseases.

His research led to the development and FDA approval of small RNA drugs, including Onpattro, a first-of-its-kind RNAi therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.